WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/096795    International Application No.:    PCT/US2004/012729
Publication Date: 11.11.2004 International Filing Date: 26.04.2004
Chapter 2 Demand Filed:    09.11.2004    
A61K 31/55 (2006.01), A61P 35/00 (2006.01), C07D 207/34 (2006.01), C07D 207/42 (2006.01), C07D 213/81 (2006.01), C07D 231/16 (2006.01), C07D 261/18 (2006.01), C07D 295/14 (2006.01), C07D 307/68 (2006.01), C07D 307/72 (2006.01), C07D 401/12 (2006.01), C07D 405/00 (2006.01), C07D 405/12 (2006.01), C07D 491/04 (2006.01)
Applicants: 3-DIMENSIONAL PHARMACEUTICALS, INC. [US/US]; 665 Stockton Drive, Suite 104, Exton, PA 19341 (US) (For All Designated States Except US).
PLAYER, Mark, R. [US/US]; (US) (For US Only).
BAINDUR, Nand [IN/US]; (US) (For US Only).
BRANDT, Benjamin, M. [US/US]; (US) (For US Only).
CHADHA, Naresh [US/US]; (US) (For US Only).
PATCH, Raymond, J. [US/US]; (US) (For US Only).
ASGARI, Davoud [IR/US]; (US) (For US Only).
GEORGIADIS, Taxiarchis [US/US]; (US) (For US Only)
Inventors: PLAYER, Mark, R.; (US).
BAINDUR, Nand; (US).
BRANDT, Benjamin, M.; (US).
CHADHA, Naresh; (US).
PATCH, Raymond, J.; (US).
ASGARI, Davoud; (US).
GEORGIADIS, Taxiarchis; (US)
Agent: LOWEN, Gregory, T.; Morgan, Lewis & Bockius LLP, 1111 Pennsylvania Avenue, N.W., Washington, DC 20004 (US)
Priority Data:
60/465,204 25.04.2003 US
Abstract: front page image
(EN)The invention is directed to compounds of formulae (I), (II) and (III), wherein A, R1, R2, R3, R4, X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.
(FR)L'invention concerne des composés de formules (I), (II) et (III), dans lesquelles A, R1, R2, R3, R4, X, Y et W sont tels que définis dans la description, ainsi que des solvates, des hydrates, des tautomères ou des sels pharmaceutiquement acceptables de ceux-ci, qui inhibent les protéines tyrosines kinases, en particulier la kinase c-fms.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)